The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Thermo Fisher Scientific has signed an agreement for the acquisition of Sanofi’s steriles manufacturing site in Ridgefield, New Jersey, US.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of ...

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

Sanofi has completed its acquisition of Blueprint, enhancing its portfolio with a commercialised therapy and expertise focused on SM.

Now is the time to invest in quantum literacy, explore proof-of-concept collaborations and monitor quantum’s integration.

Life sciences venture capital (VC) firm Omega Funds has closed its eighth fund, with capital commitments totalling $647m.

Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. With its pipeline ...

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles (herpes zoster). This ...